New COVID-19 test submitted to Brazil’s national drug regulator

The Oswaldo Cruz Foundation (Fiocruz) announced Friday (Jan. 19) it has finished the development of two new molecular tests for the diagnosis of COVID-19. One of them had its registration request submitted to Brazil’s national drug regulator Anvisa Tuesday (18). The request concerns molecular kit Inf A/Inf B/SC2, a RT-PCR test capable of differentiating between […]

Fonte